After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...

Sandoz Group said it would pay $275 million to settle claims from some plaintiffs in a generics drug pricing antitrust lawsuit in the U.S. The Swiss generics-medicine company said Tuesday that it ...

ZURICH, Feb 26 (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis (NOVN.S), opens new tab ...

Sandoz completed its long-heralded separation from Novartis on schedule this morning, with its shares trading at CHF 24 on the SIX Swiss Exchange. That valued the newly independent company at CHF ...

ZURICH, Feb 25 (Reuters) - Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 ...

Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva (ustekinumab-ttwe) in the US. From February 24, the medicine is commercially available to patients ...